: iStockAnalyst.com Symbols Feed

Get Instant Biotech Diversification

Thu, 22 Oct 2009 17:04:36 GMT

Biotechnology is a notoriously volatile industry. Shares of individual firms often skyrocket or plummet based on clinical test results. Because biotechs tend to march to the beat of their own drum--share prices are much more sensitive to clinical trial results and merger activity within the sector than they are to the economic backdrop—they can be an interesting small addition to a satellite portfolio.[More...]

The Clock Is Ticking On Micromet (MITI)

Tue, 25 Aug 2009 00:05:20 GMT

Earlier this month, Micromet (MITI) concluded an impressive public offering of $75M, approximately 20% of the company’s market cap. The offering illustrates the transformation the company has undergone from an anonymous biotech play into a recognized industry leader. This is also echoed by the growing attention from Wall St. When I first wrote about Micromet in 2007, the company was covered by a single analyst,[More...]

Curagen (NasdaqGM: CRGN)– Positive Results At ASCO 2009

Tue, 07 Jul 2009 13:25:00 GMT

Last month at the ASCO meeting, Curagen (NasdaqGM: CRGN) presented results for its lead drug, CR-011, in breast cancer and melanoma patients. CR011 had activity in both indications, however, most of the drug’s value should be ascribed to the breast cancer[More...]

Immunogen (Nasdaq: IMGN): Antibody Play

Wed, 01 Jul 2009 14:06:00 GMT

"How does one go about investing in the antibody space?" asks biotech specialist John McCamant. In The Medical Technology Stock Letter, he eyes Immunogen (NASDAQ: IMGN). "As background, T-DM1 is a second generation Herceptin that may even exceed the original in sales because the armed antibody has been more potent to date by showing effectiveness in mBC[More...]

Top Picks For ASCO 2009

Tue, 26 May 2009 11:44:28 GMT

The ASCO annual meeting, one of the most important events in the pharmaceutical industry will take place in Orlando next weekend. With over 4,000 abstracts to be presented this year, separating the wheat from the chaff is difficult, but below is an incomp[More...]

FDA, Clinical Trial Calendar Updates

Mon, 11 May 2009 21:09:10 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, s (...)[More...]

Good News For Roche, Excellent News For Immunogen

Fri, 20 Mar 2009 18:40:00 GMT

Earlier today, Roche announced positive results from a phase III study evaluating its breast cancer blockbuster, Herceptin, in gastric cancer.[More...]

Immunogen and Exelixis Defy the Myth of Recession

Sun, 21 Dec 2008 01:09:00 GMT

[More...]

Biotech Portfolio Updates- Buying More Immunogen

Thu, 16 Oct 2008 13:56:00 GMT

Investing, particularly in biotech, comes with plenty of risks and uncertainties. These uncertainties are usually results of clinical trials, which are very unpredictable and unfortunately do not end up well in most cases. Once in a while, a company and its stock price diverge in a way that substantially decreases the risk in a particular company without increasing the stock price. We believe what happened yesterday with Immunogen (IMGN) is a classic case of this phenomenon. [More...]

Immunogen – Lost In Translation

Wed, 15 Oct 2008 16:04:00 GMT

It finally happened. Yesterday, Genentech announced that they made a “go” decision to advance T-DM1 into a phase III trial. Although no official announcement is out as of yet, Genentech’s President of Product Development, Sue Hellmann, left no doubt in her prepared remarks: “Additionally, we recently made a Phase III go decision for T-DM1 in the second line setting and plan to initiate a study comparing TDM1 to a Capecitabine plus lapatinib combination in the first half of 2009.” [More...]

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2009 Financial Results

Thu, 06 Aug 2009 20:05:00 GMT

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the fiscal year and three-month period ended June 30, 2009.[More...]

ImmunoGen, Inc. Announces Webcast of Presentation at the 29th Annual Canaccord Adams Global Growth Conference

Wed, 05 Aug 2009 14:14:00 GMT

ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the 29th Annual Canaccord Adams Global Growth Conference will be webcast live. The presentation is scheduled to begin at 1:30 p.m. ET on August 12, 2009, and will be given at the Intercontinental Hotel in Boston. The presentation will provide an update on ImmunoGen.[More...]

ImmunoGen Announces Encouraging New Clinical Data with the Company’s IMGN901 Compound in the Treatment of Small-Cell Lung Cancer

Sat, 01 Aug 2009 02:26:00 GMT

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging initial efficacy, safety and tolerability clinical data with its IMGN901 product candidate in the treatment of small-cell lung cancer (SCLC). In two early-stage clinical trials that enrolled patients whose SCLC had recurred following treatment with standard chemotherapies, IMGN901 administration achieved notable tumor shrinkage and/or sustained stable disease. The compound also demonstrated encouraging activity against other CD56-expressing (CD56+) solid tumors. These clinical data are being presented at the 13th World Conference on Lung Cancer taking place in San Francisco, CA, from July 31 to Aug. 4, 2009.[More...]

ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2009 Financial Results

Thu, 30 Jul 2009 10:26:00 GMT

ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30 pm ET on Thursday, August 6, 2009 to discuss the Company’s financial results for the three-month period and fiscal year ended June 30, 2009. Management also will provide an update on the Company.[More...]

ImmunoGen, Inc. Announces Completion of Public Offering of Common Stock

Tue, 23 Jun 2009 20:00:00 GMT

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today the completion of its previously reported public offering of 5,750,000 shares of common stock. The Company received net proceeds, after underwriting discounts and commissions and estimated expenses, of approximately $38.0 million.[More...]

ImmunoGen, Inc. Announces Exercise of Over-Allotment Option

Mon, 22 Jun 2009 13:48:00 GMT

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics,announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase 750,000 shares of common stock at a public offering price of $7.00 per share.
Net proceeds, after underwriting discounts and commissions and estimated expenses, will be approximately $38.0 million.
Oppenheimer & Co. Inc. is acting as the sole book-runner for the offering and Morgan Joseph & Co. Inc. is acting as co-manager.

[More...]

ImmunoGen, Inc. Prices Public Offering of Common Stock

Thu, 18 Jun 2009 13:16:00 GMT

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that it has priced a public offering of 5,000,000 shares of its common stock at a price of $7.00 per share. Net proceeds, after underwriting discounts and commissions and expenses, will be approximately $33 million. ImmunoGen has granted the underwriters a thirty (30) day option to purchase up to an additional 750,000 shares to cover over-allotments, if any. The offering is expected to close on or about June 23, 2009, subject to satisfaction of customary closing conditions.[More...]

ImmunoGen, Inc. Announces Proposed Public Offering of Common Stock

Wed, 17 Jun 2009 20:01:00 GMT

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that it intends to offer, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering. ImmunoGen expects to grant the underwriters a thirty (30) day option to purchase up to 750,000 additional shares to cover over-allotments, if any.[More...]

ImmunoGen, Inc. Elects to Discontinue Further Internal Development of Its IMGN242 Compound

Thu, 11 Jun 2009 19:59:00 GMT

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced that the Company has elected to discontinue further internal development of its IMGN242 gastric cancer compound and to move this product candidate into its out-licensing portfolio. IMGN242 has shown encouraging safety and preliminary indications of activity in early clinical testing, but has shifted below other, higher priority programs at ImmunoGen due to its slow pace of progress.[More...]

ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented at ASCO

Sat, 30 May 2009 11:58:00 GMT

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of encouraging trastuzumab-DM1 (T-DM1) clinical data at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Orlando, Florida.[More...]